GMO国内弹性主动型ETF DRES 深 沪
已收盘 10-30 16:00:00 美东时间
30.696
-0.150
-0.49%
华盛通- 最 高30.90
- 今 开30.90
- 成交量 995股
- 最 低 30.55
- 昨 收 30.8464
- 总市值 1.50亿
- 52周最高 31.9967
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 23.8899
- 委 比 37.50%
- 总股本 488.00万
- 历史最高 31.9967
- 量 比 1.02
- 振 幅 1.13%
- 历史最低 23.8899
- 每 手 1
- 风险率 1.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie Inc. has been invited to present at the 2026 RECOVER-TLC Workshop, where Dr. Penelope Markham will share results from the Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID's neurological symptoms. The trial showed consistent improvement trends in fatigue, post-exertional malaise, and cognitive impairment, particularly in patients with severe baseline symptoms. Bezisterim demonstrated a favorable safety profile. The RECOVER-TLC ...
10-26 12:00
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Inc. announced that two abstracts from its ADDRESS-LC Phase 2 trial for Long COVID and SUNRISE-PD Phase 2 trial for Parkinson’s Disease have been accepted for presentation at ANA2026 in San Diego, October 17-20, 2026. The studies will be presented as posters. Bezisterim (NE3107), the company’s investigational drug, targets neuroinflammation and insulin resistance, showing potential benefits in reducing inflammation and improving symptoms i...
10-14 12:00
BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID
-Topline Data Release Targeted Late Summer 2026-CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for
05-26 20:06
